Mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes both the ~27 kDa glycosylated and the ~24 kDa unglycosylated forms of TIMP-3.

Recognizes the ~27 kDa glycosylated and the ~24 kDa non-glycosylated forms of TIMP-3. Does not cross-react with TIMP-1 or TIMP-2 in CaCO-2 and HEK293 cell and eye tissue.

This Anti-TIMP-3 Mouse mAb (136-13H4) is validated for use in Frozen sections, Immunoblotting, Immunofluorescence, Immunoprecipitation, Paraffin sections for the detection of TIMP-3.

Human

a synthetic peptide corresponding to amino acids 170-188 of human TIMP-3

Frozen sections (2-10 g/ml)
Immunoblotting (5 g/ml)
Immunofluorescence (not recommended)
Immunoprecipitation (not recommended)
Paraffin sections (10 g/ml, heat pre-treatment required, see application references)

Please refer to vial label for lot-specific concentration.

In 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0.

Following initial thaw, aliquot and freeze (-20°C).

Positive Control
293 or Caco-2 cells or unfixed eye tissue

Anand-Apte, B., et al. 1997. Invest. Ophthalmol. Vis. Sci.38, 817.
Butler, G.S., et al. 1997. Eur. J. Biochem.244, 653.
Fariss, R.N., et al. 1997. Am. J. Pathol.150, 323.
Vranka, J.A., et al. 1997. Curr. Eye Res.16, 102.
Ruiz, A., et al. 1996. Biochem. Biophys. Res. Commun.226, 467.
Kishnani, N.S., et al. 1995. Matrix Biol.14, 479.
Cottam, D.W. and Rees, R.C. 1993. Intl J. Oncol.2, 861.
Stetler-Stevenson, W. G., et al. 1993. FASEB J.7, 1434.
Woessner, J.F. 1991. FASEB J.5, 2145.
Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1(2), 99.

Manufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)